ADC Therapeutics has announced the appointment of Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO).
Dr Zaki will serve on the Company’s executive leadership team.
The new CMO succeeds Joseph Camardo, MD, who is stepping down from full-time work to pursue other avenues to engage with the pharmaceutical industry and patient community.
Ameet Mallik, CEO of ADC Therapeutics, said:
“We are excited to welcome Dr Zaki to ADC Therapeutics and look forward to his leadership of the development of our deep pipeline of antibody drug conjugates.
“We sincerely thank Dr Camardo for his tireless commitment to ADC Therapeutics and people living with cancer around the world.”
Dr Zaki has more than 20 years’ experience in oncology and haematology drug development.
Most recently, Dr Zaki served as Vice President & Global Head of Oncology Development at AbbVie.
Dr Zaki said:
“ADC Therapeutics is a pioneer and leader in the evolving field of antibody drug conjugates.
“I look forward to working with the Company’s experienced team of researchers to expand on their innovative science and bring more therapeutic options to those impacted by cancer worldwide.”
A commercial-stage biotechnology company, ADC Therapeutics aims to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
The company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with haematologic malignancies and solid tumours.
On December 21, 2022, ADC Therapeutics and Swedish Orphan Biovitrum AB announced that the European Commission (EC) had granted conditional marketing authorisation for the use of ZYNLONTA (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
